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Abstract Myocardial hibernation represents an adaptation to
sustained ischemia to maintain tissue vitality during severe
supply^demand imbalance which is characterized by an increased
glucose uptake. To elucidate this adaptive protective mechanism,
the regulation of anaerobic glycolysis was investigated using
human biopsies. In hibernating myocardium showing an increase
in anaerobic glycolytic flux metabolizing exogenous glucose, the
adjustment of flux through this pathway was analyzed by
flux:metabolite co-responses. By this means, a previously
unknown pattern of regulation using multisite modulation was
found which largely differs from traditional concepts of
metabolic control of the Embden^Meyerhof pathway in normal
and diseased myocardium. ß 2002 Federation of European
Biochemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
The term hibernating myocardium was coined to describe a
state of persistently impaired left ventricular function due to a
reduced coronary blood £ow which will be partially or com-
pletely restored following revascularization [1]. Clinically, hu-
man hibernating myocardium (HHM) shows an increased glu-
cose uptake [2]. This characteristic feature, which is exploited
in diagnostic means [3], is accompanied by an ampli¢ed sar-
colemmal abundance of glucose transporters [4].
In myocardial hypoperfusion, the bene¢cial e¡ects of an
augmented ATP generation by anaerobic glycolysis have
been repeatedly shown in clinical as well as in experimental
studies [5,6]. In this respect, the increased glucose uptake of
HHM takes part in the metabolic adaptation to and defense
against severe supply^demand imbalance [7] enabling the sur-
vival of this energy-depleted myocardium [8]. As a conse-
quence, the analysis of metabolic £ux and its regulation in
HHM is not only of theoretical interest. Therefore, it was
the aim of our study to investigate anaerobic glycolysis and
its regulation in HHM in order to obtain further insights into
the mechanism underlying this unique myocardial adaptation
to ischemia, which may eventually facilitate therapeutic ex-
ploitation.
To analyze the regulation of metabolic pathways, tradition-
al concepts mostly imply that control over a pathway is
achieved by action on a single pathway enzyme, which is often
assumed to be a non-equilibrium step near the pathway’s
beginning subjected to feedback inhibition, e.g. [5,9^12]. How-
ever, starting with the rise of metabolic control analysis
(MCA) [13], there is a growing body of evidence that these
comfortable, time-honoured concepts may mislead more than
enlighten. Hence, the tools of MCA were ¢rstly used in a
clinical^experimental investigation in order to obtain a state-
of-the-art analysis of anaerobic glycolytic regulation in HHM.
2. Materials and methods
2.1. Patients and study protocol
Sixteen patients with angiographically documented coronary heart
disease and a reduced left ventricular function resulting in the indica-
tion for coronary bypass surgery were studied. Informed written con-
sent from each patient for every investigation and approval of the
institutional hospital review board of the University of Freiburg
had been obtained.
To detect HHM preoperatively, established clinical methods, such
as low-dose dobutamine echocardiography, thallium-201 scintigraphy
using a stress-redistribution^reinjection protocol, radionuclide ventri-
culography and coronary angiography including left ventriculogra-
phy, were used as described in detail previously [14]. All preoperative
clinical investigations were repeated 3 months after revascularization
in order to document the extent of functional recovery of these re-
gions after restoration of adequate perfusion, thereby validating the
preoperative diagnosis ‘hibernating myocardium’.
2.2. Tissue analysis
2.2.1. Tissue sampling. Transmural Tru-cut0 needle biopsies were
removed during open-heart surgery from the beating heart before
establishment of extracorporal circulation and cardioplegic arrest.
These biopsies were immediately shock frozen in liquid nitrogen for
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high performance liquid chromatography (HPLC) and immunohisto-
chemistry or immersed in 3% glutaraldehyde bu¡ered with 0.1 M Na
cacodylate (at pH 7.4, 440 mosmol/l) for microscopy. Shock-frozen
samples were kept in liquid nitrogen until further use. Following
clinical validation of the myocardial regions as hibernating myocar-
dium (3 months postoperatively), the speci¢c examinations of the
biopsies were started.
2.2.2. Fibrosis. The ¢brotic content of HHM was determined by
electron microscopy and immunhistochemical labelling of ¢bronectin.
Three di¡erent tissue sections which were obtained from varying bi-
opsy levels were evaluated. Fibrosis was quanti¢ed employing the
point-counting method following stereological principles [15,16]. The
¢brotic area of the tissue sample was expressed as percent of the total
myocardial area.
2.2.3. Analysis of myocardial metabolites. After assessing the de-
gree of ¢brosis within the biopsies, the remaining shock-frozen tissue
was homogenized [17] and subjected to metabolite measurements us-
ing HPLC [17]. Hence, all values given represent integral metabolite
contents ([], given in Wmol/g wet weight) for a myocardial biopsy.
Considering the error arising from varying degrees of ¢brosis in con-
trol and hibernating myocardium, total myocardial metabolite con-
tents in both groups were additionally normalized to the cellular my-
ocardial fraction (CMF), providing values for myocellular content:
contentCMF  1001003fibrosis%Wcontenttotal:
Dihydroxyacetone phosphate (DHAP) and 1,3-bisphosphoglycerate
(1,3-BPG) could not be detected. The DHAP content was, therefore,
calculated from the glyceraldehyde 3-phosphate (GA3P) content as-
suming equilibrium state of the triosephosphate isomerase reaction
[18]. 2- and 3-phosphoglycerate (2PG and 3PG, respectively) were
not always clearly separated in the chromatograms, though their com-
mon peak could be easily seen. The individual proportions were cal-
culated according to the equilibrium of the phosphoglycerate mutase
(PGM) reaction
0:154  2PG3PG
The equilibria of isomerase and phosphoglyceromutase are neither
a¡ected by mild nor severe myocardial undersupply [9]. As 1,3-BPG
could not be detected, glyceraldehyde dehydrogenase (GAPDH) and
phosphoglycerate kinase (PGK) were considered as a single glycolytic
step. Since 2PG and 3PG contents were calculated, the given values
are not mathematically independent. Therefore, also PGM and eno-
lase (Eno) were put together.
2.2.4. Control tissue. The results obtained in HHM were com-
pared to left ventricular biopsies from patients undergoing operative
correction of atrial septal defects (n = 3) and from donor hearts not
used for transplantation (n = 4), representing normal human myocar-
dium.
2.2.5. Estimation of anaerobic glycolytic £ux. Estimation of anaer-
obic glycolytic £ux was performed according to the established rela-
tionship between tissue lactate accumulation and anaerobic glycolytic
£ux [19], corrected for the decrease in myocardial blood £ow (MBF)
[20], which was evidenced by an impaired preoperative thallium-201
uptake into hibernating myocardium. Unfortunately, absolute mea-
sures of anaerobic glycolytic £ux were not possible or authorized in
the clinical study performed. Nevertheless, the informations obtained
did clearly de¢ne two distinct myocardial states with unaltered (nor-
mal myocardium) and increased anaerobic glycolytic £ux (e.g. hiber-
nating myocardium) in order to compute £ux:metabolite co-re-
sponses.
Thus, anaerobic glycolytic £ux was calculated from lactate content




2.2.6. Model construction. As myocardial glycogen contents were
unchanged in HHM (indicating no net £ux from glucose 6-phosphate
(G6P) to glycogen), glycolysis was considered as linear pathway from
glucose transport (i.e. cellular uptake) via its phosphorylation to G6P
to lactate. HHM is characterized by a normal capacity and rate of
oxidative metabolism at impaired myocardial blood £ow (£ow-metab-
olism mismatch) [21,22]. Hence, aerobic glycolytic £ux was assumed
to be unchanged between HHM and control myocardium and has
thus not been taken into account for model construction.
The regulation of anaerobic glycolytic £ux along the enzymatic
reactions breaking G6P down to lactate was analyzed employing the











To the best of our knowledge, the current study represents the ¢rst
application of these established post-hoc analyses to experimentally
investigate adjustment of the Embden^Meyerhof pathway.
Table 1
Metabolite contents and parameters in normal and hibernating human myocardium
Metabolite content (nmol/mg) Total myocardium CMF
Normal Hibernation Normal Hibernation
mean S.E.M. mean S.E.M. P-value mean S.E.M. mean S.E.M. P-value
G6P 0.246 0.046 0.254 0.061 0.754 0.273 0.050 0.350 0.081 0.988
F6P 0.021 0.005 0.080 0.016 0.045 0.024 0.005 0.118 0.026 0.046
F1;6P2 0.013 0.003 0.167 0.043 0.379 0.014 0.004 0.230 0.058 0.029
GA3P 0.010 0.002 0.094 0.013 0.002 0.011 0.002 0.132 0.019 0.002
DHAP 0.229 0.038 2.261 0.322 0.002 0.255 0.043 3.164 0.460 0.002
3-PG 0.040 0.019 0.126 0.025 0.055 0.044 0.021 0.171 0.032 0.023
2-PG 0.006 0.003 0.019 0.004 0.055 0.007 0.003 0.026 0.005 0.023
PEP 0.008 0.001 0.030 0.006 0.022 0.008 0.002 0.042 0.008 0.010
Pyr 0.044 0.016 0.220 0.026 0.001 0.049 0.018 0.310 0.038 0.001
Lac 2.000 0.240 17.389 2.313 0.002 2.217 0.261 25.377 3.526 0.002
F2;6P2 0.069 0.010 0.014 0.004 6 0.0001 0.077 0.011 0.018 0.005 6 0.0001
Glycogen (C6-units WM/g) 2.999 0.369 3.769 0.527 0.359 3.328 0.408 5.503 0.835 0.137
Parameter
Anaerobic glycolytic £ux (AU) 2.217 0.261 8.574 1.428 0.006
Tl-uptake (%) 100.000 0.000 41.250 1.963 6 0.0001
Global EF (%) 26.4 2.3 46.7 3.2 6 0.0001
Regional EF (%) 24.5 2.0 55.6 3.2 6 0.0001
Fibrosis (%) 9.857 0.508 28.062 3.012 0.010
Myocardial metabolite contents, given as nmol/mg wet weight, normalized to total myocardium (left) and to the CMF (right). In addition, data
for anaerobic glycolytic £ux, thallium (Tl) uptake, global and regional ejection fraction (EF), and ¢brosis are provided. Levels of signi¢cance
(P-values calculated according to ANOVA) as shown.
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Note that it follows from the de¢nition of a co-response OJS that
J = cS0 where c is a constant. Where an enzyme converts metabolite S
to metabolite P, the co-responses OJ;S and OJ;P involve the same £ux
J, so OJ;S=OJ;P =v ln P/v ln S and if the enzyme had no change in its
mass action ratio (P/S), when v ln P =v ln S, then the co-responses
will be equal. If OJ;S is greater than OJ;P, then there has been a rel-
ative increase in product concentration and the reaction has moved
closer to equilibrium, whereas if OJ;S is smaller than OJ;P, the reaction
has moved away from equilibrium. Where only a single enzyme in a
pathway is altered, £ux^substrate co-response coe⁄cients are likely to
be less than 1 (or less than the Hill coe⁄cient for cooperative en-
zymes) [23]. Under several known physiological conditions (e.g. hyp-
oxia) [23], observed co-response coe⁄cients are larger than this; exact
mechanistic explanations of this are not known, but in theory, parallel
activation of several steps (the ‘universal method’ [24], multisite mod-
ulation [25,26], or proportional activation [27]) can account for this.
Enzymes that are extremely close to equilibrium [25] can show large
co-responses during passive adaptation to a change in metabolic £ux,
but this would imply virtually no detectable change in the displace-
ment from equilibrium, and hence v ln (P/S) D 0, with virtually
identical substrate and product co-responses as described above. A
negative £ux^substrate co-response corresponds to a classic cross-
over e¡ect, where activation of an enzyme has induced a decrease in
its substrate. Thus, the co-response coe⁄cients provide insight into
the events associated with a change in £ux.
2.2.7. Statistical analysis. Data are expressed as mean values þ
standard error. To evaluate the clinical data, the Friedman and
Dunn test, ANOVA and Sche¡e¤ test, the paired t-test and the
Mann^Whitney rank-sum test were used. Fibrosis and the metabolite
contents were analyzed using ANOVA and Sche¡e¤ testing. A value of
P6 0.05 was considered as signi¢cant di¡erence.
3. Results
3.1. Clinical Data
All patients exhibited a recovery of regional (and global)
contractile performance 3 months after revascularization,
thereby validating our clinical preoperative diagnosis ‘hiber-
nating myocardium’ (Table 1). As indicated by the restoration
of a formerly decreased thallium uptake following surgery
(Table 1), these hibernating regions showed an impaired rest-
ing perfusion before revascularization.
3.2. Metabolite contents
Contents in the metabolites of the Embden^Meyerhof path-
way and of glycogen are given in Table 1 and Fig. 1, ex-
pressed as total myocardial contents as well as normalized
to the CMF. Except for G6P and fructose 2,6-bisphosphate
(F2;6P2), HHM expresses increased contents in metabolites of
the Embden^Meyerhof pathway.
3.3. Impairment of myocardial perfusion and estimation of
anaerobic glycolytic £ux
Myocardial glycogen content was not signi¢cantly changed
in hibernating myocardium (Table 1), indicating no net £ux
between G6P and glycogen. Hence, the £ux from glucose to
G6P equals the £ux from G6P to lactate, and the reactions
from glucose to lactate may be treated as an unbranched
pathway.
Increased lactate contents in HHM stand for an elevated
anaerobic glycolytic £ux [19]. Even when corrected for an
impaired myocardial perfusion [20] (thallium-201 uptake: re-
duction to 41.25 þ 1.93% of normal, P6 0.0001), anaerobic
glycolytic £ux in HHM exhibited an approximately four-
fold increment (see Table 1). As myocardial glycogen content
did not signi¢cantly di¡er between HHM and control myo-
cardium, C6-units serving as fuel for increased £ux through
anaerobic glycolysis were provided by an augmented myocar-
dial glucose uptake of the same magnitude.
3.4. MCA of the regulation of anaerobic glycolytic £ux
The increase in anaerobic glycolytic £ux in HHM was ac-
companied by elevated contents of most metabolites of the
Embden^Meyerhof pathway (Table 1, Fig. 1). On the basis
of the calculated £ux:metabolite co-responses, the mecha-
nisms of anaerobic glycolytic regulation of the respective en-
zymatic steps could be analyzed in detail (see Table 2).
For fructose 6-phosphate (F6P), phosphoenolpyruvate
(PEP), and pyruvate (Pyr), increases in anaerobic glycolytic
£ux were associated with modest elevations in metabolite con-
tent, and clearly positive co-response coe⁄cients could be cal-
culated. These data indicate that the reaction velocities of
phosphofructokinase-1 (PFK-1), pyruvate kinase (PK) and
Fig. 1. Mean values and standard errors of myocardial metabolite
contents (normalized to CMF) in control (low anaerobic glycolytic
£ux) and hibernating human myocardium (increased anaerobic gly-
colytic £ux).
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lactate dehydrogenase (LDH) increase sensitively with raising
substrate concentrations. As the values for O were in the
range between 0.5 and 6 1.0, £ux determining (albeit passive)
roles for these enzymes can be assumed [13,23,26,28]. Con-
trary to expectations from traditional accounts of glycolytic
regulation, there is no evidence of a ‘cross-over’ from action
of e¡ectors at PFK-1; the larger co-response to substrate in-
dicates that the enzyme has moved closer to equilibrium, but
that this can be accounted for by an increase in substrate
concentration.
In the case of PGM/Eno, where values for O in the range of
+1 could be calculated, the signi¢cantly larger co-response to
its substrate 3PG than to its product PEP (P = 0.0056) indi-
cates that this pair has had an increase in product/substrate
ratio, implying that they have moved closer to equilibrium
and that were, therefore, more displaced from equilibrium
previously. How this pair could move closer to equilibrium
at a higher net £ux is not explicable on current knowledge of
the control of the pathway. Both, the signi¢cantly di¡erent
O-value of 3PG ^ compared with the O-values of PEP, Pyr
and F6P, as computed by ANOVA ^ and the observed alter-
ation in enzyme kinetics indicate an active £ux-adjusting role
for this step.
For fructose 1,6-bisphosphate (F1;6P2) and GA3P, the in-
crease in anaerobic glycolytic £ux did occur at large incre-
ments in metabolite content, and only small values for O
could be calculated. This pattern of such an only weak in-
crease in reaction velocity in response to an increment in
substrate concentration suggests passive, minor roles of these
steps for £ux determination [13,23,26,28].
For G6P, the increase in £ux could be documented at vir-
tually stable metabolite contents, resulting in a very high co-
response coe⁄cient. Hence, the acceleration in reaction veloc-
ity of glucosephosphate isomerase (GP-iso) is independent of
the content of its substrate. This pattern implies that the be-
havior of this step of the Embden^Meyerhof pathway cannot
be explained by passive substrate kinetics, nor closeness to
equilibrium, since the very much larger value of G6P co-re-
sponse to the F6P co-response shows that the mass action
ratio of this enzyme changes relevantly, and in opposite direc-
tion to that required to account for the £ux increase. Other
regulatory mechanisms which allow to control this enzyme’s
reaction velocity independent of substrate concentration are
apparently operative. Such an enzymatic behavior is charac-
teristic for steps actively participating in £ux adjustment
[13,23,26,28].
4. Discussion
Using the tools of MCA, our paper is the ¢rst to analyze
anaerobic glycolytic £ux and its regulation in hibernating hu-
man myocardium. According to the data obtained, HHM ex-
hibited an increased anaerobic glycolytic £ux, which was fu-
eled by a corresponding increment in myocardial glucose
uptake. The analysis of £ux:metabolite co-responses allowed
us to characterize the mechanism of enzymatic regulation of
individual glycolytic steps as well as the distribution of £ux
control along the Embden^Meyerhof pathway.
4.1. Increased anaerobic glycolytic £ux in HHM: impact on
augmented ischemic tolerance.
In spite of varying concepts concerning the pathophysiolo-
gy of HHM, its increased uptake of radiolabelled glucose
tracers (18-£uoro-deoxyglucose) represents the gold standard
for its clinical diagnosis [3]. However, the augmented glucose
uptake of HHM may not only be of diagnostic value [2], but
may also contribute to the metabolic adaptation of HHM
enabeling this energy-depleted myocardium to better with-
stand severe supply^demand imbalance [7].
Myocardial survival in states of undersupply critically de-
pends on the cellular energy status [29]. To limit energy de¢cit
in conditions of energy shortage, as observed during hypoxia
and ischemia, myocardial ATP formation may be ampli¢ed by
increasing substrate chain phosphorylation in anaerobic gly-
colysis. By this means, the rate of ATP-synthesis is increased
when reduced oxygen-availability becomes the limiting factor
[30^33]. This mechanism was repeatedly shown to enable
myocardial survival in various states of myocardial hypoper-
fusion [5,6].
In this respect, our data are consistent with the view that an
accelerated £ux through anaerobic glycolysis may represent an
e¡ective metabolic adaptation to better withstand severe sup-
ply^demand imbalance also in HHM, since any increase in
anaerobic glycolytic £ux indicates a corresponding increment
in ATP provision. As this rise is fueled by an elevated myo-
cardial glucose uptake, our data provide kinetic evidence for
the ampli¢ed sarcolemmal abundance of glucose transporters
in HHM [4].
4.2. Regulation of anaerobic glycolytic £ux
The values calculated for O [23] allowed us to classify the
glycolytic enzymes into four groups depending on the mech-
anism used for controlling and determining £ux through this
Table 2
Metabolite O-value Enzyme Change in kinetics in
HHM?
Regulatory mechanism Role for £ux
regulation
G6P 10.13 þ 2.018 GP-iso active independent of substrate content or closeness to
equilibrium
major
F6P 0.72 þ 0.050 PFK-1 passive substrate kinetics major
F1;6P2 0.19 þ 0.015 FBP-aldo passive substrate kinetics minor
GA3P 0.25 þ 0.023 GAPDH/
PGK
passive substrate kinetics minor
3PG 1.00 þ 0.428 PGM/Eno active closeness to equilibrium by unknown mechanism major
PEP 0.72 þ 0.032 PK passive substrate kinetics major
Pyr 0.54 þ 0.175 LDH passive substrate kinetics major
Lac 0.27 þ 0.012
Flux:metabolite co-responses (O, mean þ S.E.M.) for metabolites of anaerobic glycolysis. In addition, informations about the enzymes of the
Embden^Meyerhof pathway with respect to kinetic changes in HHM and proposed regulatory mechanisms are provided. FBP-aldo, fructosebis-
phosphate aldolase
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pathway:
1. According to our data, aldolase and GAPDH/PGK show a
passive behavior in response to an increased net £ux in
terms of enzyme kinetics, whereby the low values for O
suggest minor roles for £ux determination.
2. The £ux:metabolite co-responses obtained for PFK-1, PK
and LDH, however, indicate that these enzymes do more
relevantly determine glycolytic £ux. This is achieved by
sensitively (albeit passively) increasing these enzymes’ reac-
tion velocities in response to elevations in their substrate
concentrations according to classical substrate kinetics.
3. In contrast to these inactively acting enzymes in terms
of enzyme kinetics, the signi¢cant changes in PGM/Eno
with respect to their equilibrium positions observed in
HHM and the signi¢cantly higher values calculated for O
at these glycolytic step(s) ^ compared to the O-values for
F6P, PEP and Pyr ^ were not consistent with a passive
response to the change in £ux. In this case, an active alter-
ation of enzyme kinetics for the adjustment of £ux is in-
dicated.
4. For GP-iso, for which an active alteration in enzyme ki-
netics in HHM is also obvious, a di¡erent means of enzy-
matic regulation independent of substrate concentration,
consistent, e.g., with an alteration of enzyme reaction ve-
locity by external e¡ectors [34], could be shown.
Taken together, the evaluation of the £ux:metabolite co-
responses suggests that the control of anaerobic glycolytic
£ux is achieved using £ux modulation at several sites along
the Embden^Meyerhof pathway, which is consistent with the
concept of multisite modulation [25]. At GP-iso and PGM/
Eno, altered enzymatic properties are suggested by our anal-
ysis, indicating their active participation in £ux control. For
the remaining enzymes no clear evidence of changed enzyme
behavior could be seen, though the £ux:metabolite co-re-
sponses for PFK-1, PK and LDH still suggest their contribu-
tion to the determination of £ux through the Embden^Meyer-
hof pathway. For GAPDH/PGK and aldolase, ¢nally, the low
values for O are not in favor of important contributions of
these enzymes.
With respect to the number and location of regulatory, £ux-
adjusting sites along the Embden^Meyerhof pathway, this
¢rst analysis using £ux:metabolite co-responses in an clini-
cal^experimental study strongly contradicts traditional con-
cepts for the control of the Embden^Meyerhof pathway in
normal and diseased myocardium, as these models often pos-
tulate that £ux through glycolysis is almost exclusively con-
trolled by the behavior of PFK-1 [5,9,11,12]. Though the data
presented still suggest that PFK-1 is (passively) involved in
£ux determination, the time-honoured ‘key regulatory role’
[35] is not con¢rmed by our observations. Moreover, a pre-
dominant role for PFK-1 in £ux regulation can only be hardly
put into accordance with the ¢nding that the contents for
F2;6P2, which is a potent positive e¡ector of PFK-1 in vitro
[35], were found to be decreased in HHM.
4.3. Limitations of the study
4.3.1. Myocardial enzyme content. As HHM represents a
chronical process, it must be assumed that alterations not only
in metabolite content but also in protein composition might
occur. Though data for HHM itself are lacking, this has re-
cently been shown for human myocardium failing for other
reasons [36^40]. Since the HHM is believed to su¡er from
supply^demand imbalance, it might be expected to show a
response similar to the typical pattern of hypoxic cells : coor-
dinate induction of glycolytic enzymes and some repression of
mitochondrial enzymes [26,41]. If this were to account for the
£ux changes here, then upregulation of all the enzymes by the
same factor [42] would allow an increase in £ux without
changes in intermediate metabolite levels. In fact, in hypoxia,
the relative increases in low-activity enzymes such as PFK and
PK are observed to be somewhat greater than in enzymes such
as GP-iso and PGM/Eno for which we have evidence of ac-
tivity changes.
4.3.2. Estimation of anaerobic glycolytic £ux. Anaerobic
glycolytic £ux, as it can be easily assessed in animal studies,
could not be directly measured in our clinical study for meth-
odological and ethical reasons. Therefore, anaerobic glycolytic
£ux had to been estimated from myocardial lactate content,
which was corrected for a reduced lactate washout as a de-
creased perfusion of hibernating myocardium. By this means,
we were able to clearly di¡erentiate two distinct metabolic
myocardial states with an unaltered (normal myocardium)
and an increased anaerobic glycolytic £ux (HHM), allowing
to apply £ux:metabolite co-responses to analyze anaerobic
glycolytic regulation.
The measurements of metabolites were made on myocardial
biopsies, representing a heterogenous material. Thus, it is pos-
sible that there might have been regional di¡erences in metab-
olite contents and thus also in the calculated £ux:metabolite
co-responses. Due to the sample preparation used, these re-
gional di¡erences could not be considered and the values giv-
en for O might not truly represent the £ux:metabolite co-
responses existing at the respective enzymes themselves. These
unavoidable limitations must be considered.
Since HHM was shown to contain a normal rate and ca-
pacity of oxidative metabolism [21], aerobic glycolysis was
assumed to be unchanged between both groups and was
thus not considered for model construction. However, we
cannot exclude di¡erences in aerobic glycolytic rate between
normal and hibernating myocardium with certainty. As hypo-
perfused myocardium switches from the preferential use of
fally acids to carbohydrates as a fuel for oxidative metabolism
[32] resulting in an increased aerobic glycolytic £ux, our mod-
el might have underestimated total (i.e. aerobic plus anaero-
bic) £ux through the Embden^Meyerhof pathway. These pos-
sible limitations must be taken into account.
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